ACTN2

ACTN2 encodes alpha-actinin-2, a sarcomeric Z-disc protein that crosslinks actin filaments, anchors structural components, and serves as a signaling scaffold essential for striated muscle function. Its calponin-homology actin-binding domain mediates F-actin association, and pathogenic mutations in this domain reduce binding affinity and impair Z-disc localization, leading to sarcomeric disorganization and force impairment in cardiomyocytes and skeletal muscle (PMID:27287556, PMID:30701273). CDK1 phosphorylates ACTN2 at T308, and dephosphorylation upon cell-cycle exit is required for incorporation into nascent sarcomeres, coupling differentiation to myofibril assembly (PMID:41953953). Disease-causing variants operate through two distinct mechanisms — protein destabilization activating the ubiquitin-proteasome system and autophagy (PMID:36078153, PMID:36899856), or protein-extending frameshifts that drive cytoplasmic aggregation (PMID:39095936) — while loss of ACTN2 function promotes cardiac hypertrophy through excessive MAPK/ERK signaling (PMID:38990270).

1. 2016 High

   Establishing how HCM-associated mutations in the actin-binding domain alter alpha-actinin-2 structure and function resolved the molecular basis by which point mutations disrupt Z-disc integrity.

   Evidence X-ray crystallography of ABD mutants, F-actin co-sedimentation, and live-cell imaging of mEos2-tagged ACTN2 in adult cardiomyocytes

   PMID:27287556

   Open questions at the time

   • Whether reduced F-actin affinity alone is sufficient to cause disease in vivo
   • No titin-interaction data for these mutants
   • Structural consequences in the context of full-length dimeric protein not resolved
2. 2019 High

   Demonstrating that ACTN2 mutations cause sarcomeric disorganization and impaired muscle force in vivo established alpha-actinin-2 as causative for congenital myopathy (actininopathy) in animal models.

   Evidence Zebrafish microinjection and AAV transduction of mouse muscle with force measurement and electron microscopy

   PMID:30701273

   Open questions at the time

   • Whether phenotype is due to dominant-negative or haploinsufficiency mechanism
   • Long-term cardiac phenotype not assessed in these models
3. 2020 Medium

   Identifying XBP1-mediated transcriptional upregulation of ACTN2 under ER stress revealed that UPR signaling can modulate the ACTN2/ACTN3 expression ratio in muscle.

   Evidence Promoter-reporter assay, siRNA knockdown of XBP1, and qRT-PCR in C2C12 myotubes under chemical ER stress

   PMID:32451822

   Open questions at the time

   • No direct ChIP evidence for XBP1 binding at the ACTN2 promoter
   • Protein-level changes not observed despite mRNA increase
   • Physiological relevance in vivo unknown
4. 2022 High

   Showing that a missense ACTN2 variant triggers proteopathy — activating both the ubiquitin-proteasome and autophagy-lysosomal pathways — in human cardiomyocytes established protein quality control failure as a disease mechanism distinct from simple loss of F-actin binding.

   Evidence CRISPR knock-in hiPSC-CMs with proteomics, RNA-seq, immunofluorescence, and engineered heart tissue force measurement

   PMID:36078153

   Open questions at the time

   • Whether proteopathy is a universal feature of all destabilizing variants
   • Relative contribution of proteasomal versus autophagic degradation not delineated
5. 2023 High

   Demonstrating that a destabilizing ACTN2 variant causes embryonic lethality when homozygous and cardiomyopathy features when heterozygous in mice confirmed dose-dependent pathogenicity of protein-destabilizing mutations in vivo.

   Evidence Mouse knock-in model with echocardiography, proteomics, and histology

   PMID:36899856

   Open questions at the time

   • Whether mitochondrial dysfunction is a direct consequence of ACTN2 destabilization or secondary
   • Heterozygous female phenotype not fully characterized
6. 2024 Medium

   Distinguishing dominant protein-extending frameshifts (which aggregate) from recessive missense variants (which do not) clarified that at least two distinct molecular mechanisms — aggregation versus destabilization — underlie actininopathies.

   Evidence C2C12 transfection with frameshift and missense ACTN2 variants, immunofluorescence for aggregate detection

   PMID:39095936

   Open questions at the time

   • Aggregation assay performed in non-muscle lineage C2C12 cells before differentiation
   • Toxicity of aggregates versus loss of functional protein not dissected
   • No in vivo validation of aggregation phenotype
7. 2024 High

   Identifying CDK1-dependent phosphorylation at T308 as a switch that prevents premature sarcomere assembly in proliferating cells linked cell-cycle regulation to myofibrillogenesis for the first time through ACTN2.

   Evidence In vitro CDK1 kinase assay and CRISPR knock-in of T308A/T308D variants in C2C12 cells with sarcomere and proliferation readouts

   PMID:41953953

   Open questions at the time

   • In vivo relevance of T308 phosphorylation not demonstrated
   • Whether other CDK substrates cooperate in this switch
   • Phosphatase responsible for T308 dephosphorylation upon differentiation not identified
8. 2024 Medium

   Revealing that ACTN2 loss-of-function promotes cardiac hypertrophy through MAPK/ERK hyperactivation provided a signaling explanation for why haploinsufficiency can cause hypertrophic cardiomyopathy.

   Evidence siRNA knockdown in H9c2 cells under dexamethasone stress, transcriptome analysis, ERK inhibitor rescue

   PMID:38990270

   Open questions at the time

   • Only one cell line tested; no primary cardiomyocyte or in vivo validation
   • How ACTN2 normally restrains ERK signaling is mechanistically unclear
   • Dexamethasone stress model may not recapitulate physiological hypertrophic stimuli
9. 2025 Medium

   Demonstrating that ACTN2 interacts with PDLIM1 to sustain Hippo-YAP signaling in vascular smooth muscle cells expanded the functional repertoire of alpha-actinin-2 beyond sarcomeric crosslinking to mechanosensitive pathway regulation.

   Evidence Co-IP for ACTN2-PDLIM1, ChIP-qPCR for H3K4me3 at ACTN2 locus, shRNA/overexpression rescue with YAP pathway readout

   PMID:40881324

   Open questions at the time

   • ACTN2-PDLIM1 interaction shown by single Co-IP without reciprocal validation in an independent system
   • Relevance of this pathway in cardiomyocytes versus smooth muscle cells not compared
   • Direct versus indirect effect on YAP not resolved

• The phosphatase that dephosphorylates T308 upon cell-cycle exit, the structural basis of ACTN2-ACTN4 heterodimerization at the Z-disc, and whether MAPK/ERK hyperactivation is the primary driver of hypertrophy in ACTN2 haploinsufficiency in vivo remain unresolved.
• No phosphatase identified for T308 dephosphorylation
• ACTN2-ACTN4 heterodimer structure and stoichiometry at the Z-disc not resolved by experimental methods
• In vivo validation of ERK-dependent hypertrophy pathway in ACTN2-deficient hearts lacking